Tandem Diabetes Care, Inc.

Tandem Diabetes Care (TNDM) plans to file an application seeking FDA approval for use of its Control-IQ technology in t: slim X2 insulin pumps for patients aged 14 and above.

Tandem Diabetes Care’s (TNDM) automated insulin delivery system predicts a patient’s glucose levels in advance and suspends insulin dosage if there is a chance of a hypoglycemic event.

Tandem Diabetes Care (TNDM) reaffirmed its fiscal 2019 international market revenue guidance of $45 million to $50 million.

In the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%.

In its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue guidance.

Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic and Johnson & Johnson.

Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.

After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid.

On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

On September 25, Tandem Diabetes Care’s stock price closed at $47.84, which represents ~7.43% growth from the close of $44.53 on September 24.

The rating downgrade from Baird on September 14 triggered the downward trend in Tandem stock.

Tandem Diabetes Care (TNDM), one of the best-performing medical device companies in 2018, has reported a YoY rise of 1,814.4% YTD.

Tandem is developing a next-generation hardware platform, t:sport Insulin Delivery System, which is expected to be half the size of the t:slim pump.

Tandem Diabetes Care’s (TNDM) t:slim X2 with Basal-IQ, which is its automated insulin delivery algorithm, was approved by the FDA in June.

On August 2, Tandem Diabetes Care (TNDM) stock closed at $31.39. That’s a 9.87% rise from its prior day’s close of $28.57.

Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.

Tandem Diabetes Care (TNDM) incurred selling, general, and administrative expenses of $20.9 million in Q1 2018 as compared with $22.8 million in Q1 2017.

Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.

Tandem Diabetes Care (TNDM) witnessed a 44% rise between May 11 and May 18.

Tandem Diabetes Care (TNDM) rose 21% in the week ended March 29, 2018, to close at $4.96.

On October 5, 2017, & Johnson’s (JNJ) diabetes care company, Animas, announced its plans to exit the insulin pump business.